Guardant Health, Inc. (GH)
| Market Cap | 20.19B +250.8% |
| Revenue (ttm) | 1.08B +39.6% |
| Net Income | -433.19M |
| EPS | -3.40 |
| Shares Out | 132.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,497,369 |
| Open | 147.33 |
| Previous Close | 148.07 |
| Day's Range | 144.85 - 153.01 |
| 52-Week Range | 40.36 - 174.08 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 169.00 (+10.97%) |
| Earnings Date | Jul 30, 2026 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $169.0, which is an increase of 10.97% from the latest price.
News
Guardant Health price target raised to $190 from $160 at Guggenheim
Guggenheim raised the firm’s price target on Guardant Health (GH) to $190 from $160 and keeps a Buy rating on the shares. The firm says its Q2 web traffic data…
Guardant Health price target raised to $200 from $127 at TD Cowen
TD Cowen raised the firm’s price target on Guardant Health (GH) to $200 from $127 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics…
Guardant Health price target raised to $205 from $135 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $205 from $135 and keeps a Buy rating on the shares. The firm updated its model…
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market ...
Guardant Health price target raised to $175 from $130 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Guardant Health (GH) to $175 from $130 and keeps an Overweight rating on the shares. The firm is updating its model ahead…
Guardant Health price target raised to $215 from $150 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Guardant Health (GH) to $215 from $150 and keeps a Buy rating on the shares.
Guardant Health price target raised to $200 from $160 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Guardant Health (GH) to $200 from $160 and keeps an Outperform rating on the shares. The firm’s Q2 preview…
Guardant Health price target raised to $190 from $135 at BofA
BofA raised the firm’s price target on Guardant Health (GH) to $190 from $135 and keeps a Buy rating on the shares. Guardant Health is expected to benefit from recent…
Guardant news ‘meaningful positive’ but impact modest, says TD
TD Cowen says shares of Guardant Health (GH) traded up 14% after its Shield colorectal screening test received coverage from UnitedHealth (UNH) starting August 1 for average risk individuals ages…
Guardant Health price target raised to $200 from $175 at Bernstein
Bernstein analyst Eve Burstein raised the firm’s price target on Guardant Health (GH) to $200 from $175 and keeps an Outperform rating on the shares. On July 1, 2026, Guardant…
Guardant Health Shield blood test now covered by UnitedHealth
Guardant Health (GH) announced its Shield blood test for colorectal cancer screening is now covered for eligible UnitedHealth (UNH) Group members, which the company says makes it “the first major…
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covere...
Guardant Health price target raised to $190 from $160 at BTIG
BTIG raised the firm’s price target on Guardant Health (GH) to $190 from $160 and keeps a Buy rating on the shares. The shares are rising today on the back…
Citi says UnitedHealth coverage for Shield ‘another positive step’ for Guardant
Citi views United Healthcare (UNH) announcing coverage for the Shield CRC screening test, starting August 1, as “another positive catalyst” for Shield and Guardant Health (GH). This expansion of the…
Guardant rallies after UnitedHealth covers colorectal cancer test
Shares of Guardant Health (GH) are moving higher after UnitedHealth (UNH) announced coverage for the company’s Guardant Shield, a blood-based colorectal cancer screening. Guardant is up 7%, or $10.61,...
Guardant Health price target raised to $160 from $135 at Guggenheim
Guggenheim raised the firm’s price target on Guardant Health (GH) to $160 from $135 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select…
Guardant Health resumed with an Outperform at Bernstein
Bernstein resumed coverage of Guardant Health (GH) with an Outperform rating and $175 price target following a return from maternity leave. “Many things” are going right for the life science…
Guardant Health price target raised to $150 from $120 at Barclays
Barclays raised the firm’s price target on Guardant Health (GH) to $150 from $120 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Guardant Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approvals, with all proposals passing by majority vote. No questions were raised by stockholders, and final results will be filed with the SEC.
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the C...
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transact...
Guardant Health initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Guardant Health (GH) with an Outperform rating and $185 price target The firm cites the company’s “structural growth, near-term catalysts, and meaningful average sell...
Guardant Health announces U.S. FDA approved Guardant360 CDx
Guardant Health (GH) announced that the U.S. Food and Drug Administration, FDA, has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos, the first targeted therapy ...
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360®...